

Copyright Notice

CPT codes, descriptions and other data only are copyright 2024 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply. Fee schedules, relative value units, conversion factors and/or related components aren't assigned by the AMA, aren't part of CPT, and the AMA isn't recommending their use. The AMA doesn't directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Coverage & Billing Information for the 2025 Quarterly Code Update

Background

Iowa Medicaid has reviewed the **Q4 2025** Billing Code Update to determine coverage and billing guidelines. The Iowa Medicaid coverage and billing information provided in this bulletin is effective **October 1, 2025**. This bulletin serves as a notice of the following information:

Table 1

- New Current Procedural Terminology (CPT®) and Healthcare Common Procedure Coding System (HCPCS) codes included in the **Q4 2025** code update. Coverage and billing information for these codes applies to dates of service on or after **October 1, 2025**.

Table 2

- New Current Dental Terminology (CDT©) codes included in the **Q4 2025** code update. Coverage and billing information for these codes applies to dates of service on or after **N/A**.

Table 3

- Modifiers included in the code update. Coverage and billing information for these codes applies to dates of service on or after **N/A**.

Table 4

- CPT©, CDT©, & HCPCS codes that would be considered Outpatient Hospital on or after **October 1, 2025**.

Table 5

- Non-Covered Codes - CPT©, CDT© & HCPCS codes that have been thoroughly reviewed and Iowa Medicaid has decided not to cover effective **October 1, 2025**.

Table 6

- Deleted Codes - CPT©, CDT© & HCPCS codes that have been discontinued effective **September 30, 2025**.

The **Q4 2025** code update may include modifications to descriptions for some existing HCPCS/CPT codes. These modifications are available for reference or download from the CMS website at www.cms.gov.

The **Q4** code update also includes a list of deleted codes. These codes are available for reference or download from the CMS website at cms.gov. If there is a replacement

code, Iowa Medicaid has added the replacement code for which there were deleted codes effective as of **October 1, 2025**.

Iowa Medicaid will update the fee schedule as rates become available.

Managed Care Organization (MCOs) establish and publish reimbursement, PA, and billing information within the managed care delivery system. Questions about managed care PA should be directed to the MCP with which the member is enrolled.

Iowa Medicaid Provider Services:

- Phone: 1-800-338-7909
- Email: imeproviderservices@hhs.iowa.gov

Wellpoint Iowa, Inc.:

- Phone: 1-833-731-2143
- Email: ProviderSolutionsIA@wellpoint.com
- Website: <https://www.provider.wellpoint.com/iowa-provider/home>

Iowa Total Care:

- Phone: 1-833-404-1061
- Email: providerrelations@iowatotalcare.com
- Website: <https://www.iowatotalcare.com>

Molina Healthcare of Iowa:

- Phone: 1-844-236-1464
- Email: iaproviderrelations@molinahealthcare.com
- Website: <https://www.molinahealthcare.com/providers/ia/medicaid/home.aspx>
- Provider portal: <https://www.availity.com/molinahealthcare>

Table 1 – CPT© & HCPCS Codes

Code	Description
A9612	Injection, fluorescein, 1 mg
A9616	Gallium ga-68 gozetotide (gozellix), diagnostic, 1 millicurie
C9305	Injection, nipocalimab-aahu, 3 mg
C9306	Injection, telisotuzumab vedotin-tllv, 1 mg
J0163	Injection, epinephrine in sodium chloride (endo), 0.1 mg
J0164	Injection, epinephrine in sodium chloride (baxter), 0.1 mg
J0458	Injection, aztreonam/avibactam, 7.5 mg/2.5 mg (10 mg)
J0462	Injection, atropine sulfate, not therapeutically equivalent to j0461, 0.01 mg
J0525	Injection, cefotetan disodium, 10 mg
J0582	Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mg
J0614	Injection, treosulfan, 50 mg
J0668	Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg
J0675	Injection, carboprost tromethamine, 0.1 mg
J0738	Injection, lenacapavir, 1 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)
J0752	Oral, lenacapavir, 300 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)
J0759	Injection, clevidipine butyrate, 1 mg
J1370	Injection, esomeprazole sodium, 1 mg
J1612	Injection, glucagon (gvoke), 0.01 mg
J1807	Injection, ethacrynate sodium, 1 mg
J1809	Injection, fosdenopterin, 0.1 mg
J1834	Injection, isoniazid, 1 mg
J2151	Injection, mannitol, 250 mg
J2291	Injection, nafcillin sodium (baxter), 20 mg
J3290	Injection, tranexamic acid, 5 mg

Code	Description
J3402	Injection, remestemcel-l-rknd, per therapeutic dose
J3403	Revakinagene taroretcel-lwey, per implant
J7173	Injection, concizumab-mtci, 0.5 mg
J7174	Injection, fitusiran, 0.04 mg
J9011	Injection, datopotamab deruxtecan-dlnk, 1 mg
M0237	Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving corticosteroids and require oxygen, ventilation, or ECMO only, includes infusion and monitoring, NOC, first dose
M0238	Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving corticosteroids and require oxygen, ventilation, or ECMO only, includes infusion and monitoring, NOC, second dose
Q0237	Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO only, 1 mg
Q5154	Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg
Q5155	Injection, aflibercept-jbvf (yesafili), biosimilar, 1 mg
Q5156	Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg
Q5157	Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg
Q5158	Injection, denosumab-bnht (bomynta/conexxence), biosimilar, 1 mg

Table 2 – CDT©

Code	Description
N/A	N/A

Table 3 – Modifiers

Code	Description
N/A	N/A

Table 4 – Outpatient Hospital

Code	Description
A9612	Injection, fluorescein, 1 mg
A9616	Gallium ga-68 gozetotide (gozellix), diagnostic, 1 millicurie
C9305	Injection, nipocalimab-aahu, 3 mg
C9306	Injection, telisotuzumab vedotin-tllv, 1 mg
J0163	Injection, epinephrine in sodium chloride (endo), 0.1 mg
J0164	Injection, epinephrine in sodium chloride (baxter), 0.1 mg
J0458	Injection, aztreonam/avibactam, 7.5 mg/2.5 mg (10 mg)
J0462	Injection, atropine sulfate, not therapeutically equivalent to j0461, 0.01 mg
J0525	Injection, cefotetan disodium, 10 mg
J0582	Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mg
J0614	Injection, treosulfan, 50 mg
J0668	Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg
J0675	Injection, carboprost tromethamine, 0.1 mg
J0738	Injection, lenacapavir, 1 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)
J0752	Oral, lenacapavir, 300 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)
J0759	Injection, clevidipine butyrate, 1 mg
J1370	Injection, esomeprazole sodium, 1 mg
J1612	Injection, glucagon (gvoke), 0.01 mg
J1807	Injection, ethacrynate sodium, 1 mg
J1809	Injection, fosdenopterin, 0.1 mg

Code	Description
J1834	Injection, isoniazid, 1 mg
J2151	Injection, mannitol, 250 mg
J2291	Injection, nafcillin sodium (baxter), 20 mg
J3290	Injection, tranexamic acid, 5 mg
J3402	Injection, remestemcel-l-rknd, per therapeutic dose
J3403	Revakinagene taroretcel-lwey, per implant
J7173	Injection, concizumab-mtci, 0.5 mg
J7174	Injection, fitusiran, 0.04 mg
J9011	Injection, datopotamab deruxtecan-dlnk, 1 mg
M0237	Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving corticosteroids and require oxygen, ventilation, or ECMO only, includes infusion and monitoring, NOC, first dose
M0238	Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving corticosteroids and require oxygen, ventilation, or ECMO only, includes infusion and monitoring, NOC, second dose
Q0237	Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO only, 1 mg
Q5154	Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg
Q5155	Injection, aflibercept-jbvf (yesafili), biosimilar, 1 mg
Q5156	Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg
Q5157	Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg
Q5158	Injection, denosumab-bnht (bomynta/conexxence), biosimilar, 1 mg

Table 5 - Noncovered Codes

Code	Description
A2036	Cohealyx collagen dermal matrix, per square centimeter

Code	Description
A2037	G4derm plus, per milliliter
A2038	Marigen pacto, per square centimeter
A2039	Innovamatrix fd, per square centimeter
A4288	Valve for breast pump, replacement
C1740	Leadless electrode, transmitter, battery (all implantable), for sequential left ventricular pacing
C1741	Anchor/screw for bone fixation, absorbable (implantable)
C1742	Pressure monitoring system, compartmental intramuscular (implantable), continuous, including all components (e.g., introducer, sensor), excludes mobile (wireless) software application
C8006	Insertion of pleural-peritoneal shunt with intercostal pump chamber, including imaging, injection(s) of contrast with radiological supervision and interpretation, when performed
E0150	Combination wheeled walker with seat and transport chair, folding, adjustable or fixed height
E0658	Segmental pneumatic appliance for use with pneumatic compressor, integrated, 2 full arms and chest
E0659	Segmental pneumatic appliance for use with pneumatic compressor, integrated, head, neck and chest
J0570	Buprenorphine implant, 74.2 mg
J0681	Injection, ceftobiprole medocaril sodium, 3 mg
L1007	Scoliosis orthosis, sagittal-coronal control provided by a rigid lateral frame, extends from axilla, to trochanter, includes all accessory pads, straps, and interface, custom fabricated
L5657	Addition to lower extremity prosthesis, manual/automated adjustable air, fluid, gel or equal socket insert for limb volume management, any materials
L6034	Partial hand, finger, & thumb prosthesis w/out prosthetic digit(s)/thumb, amputation at transmetacarpal level, including flexible or non-flexible interface, molded to patient model, not including inserts described by L6692
L6035	Single prosthetic digit, mechanical, can include metacarpophalangeal, proximal interphalangeal, and/or distal interphalangeal joint(s), with or without locking mechanism, initial issue or replacement
L6036	Prosthetic thumb, mechanical, can include metacarpophalangeal, interphalangeal joint(s), with or without locking mechanism, can include flexion or extension assist, any material, attachment, initial issue or replacement
L6038	Addition to single prosthetic digit or thumb, mechanical, attachment, multiaxial and/or internal/external rotation/abduction/adduction mechanism, with or without locking feature, any material

Code	Description
L6039	Passive prosthetic digit or thumb prosthesis not including hand restoration partial hand, full or partial, custom made, any material, initial or replacement, per single passive prosthetic digit or thumb
M0235	IV infusion, monoclonal antibody products for post-exposure prophylaxis or tx of covid-19, for hospitalized pts receiving corticosteroids and oxygen, ventilation, or ECMO, includes infusion & monitoring, NOC, first dose.
M0236	IV infusion, monoclonal antibody products for post-exposure prophylaxis or tx of covid-19, for hospitalized pts receiving corticosteroids and oxygen, ventilation, or ECMO, includes infusion & monitoring, NOC, second dose.
Q0235	Injection, monoclonal antibody products for post-exposure prophylaxis or treatment of covid-19, for hospitalized patients receiving corticosteroids and oxygen, ventilation, or ECMO only, not otherwise classified, 1 mg
Q4383	Axolotl graft ultra, per square centimeter
Q4384	Axolotl dualgraft ultra, per square centimeter
Q4385	Apollo ft, per square centimeter
Q4386	Acesso trifaca, per square centimeter
Q4387	Neothelium ft, per square centimeter
Q4388	Neothelium 4l, per square centimeter
Q4389	Neothelium 4l+, per square centimeter
Q4390	Ascendion, per square centimeter
Q4391	Amnioplast double, per square centimeter
Q4392	Grafix duo, per square centimeter
Q4393	Surgraft ac, per square centimeter
Q4394	Surgraft aca, per square centimeter
Q4395	Acelagraft, per square centimeter
Q4396	Natalin, per square centimeter
Q4397	Summit aaa, per square centimeter
Q5159	Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg

Code	Description
0575U	Transplantation med (liver allograft rejection), mirna gene expression profiling by rt-pcr of 4 genes (mir-122, mir-885, mir-23a housekeeping, spike-in control), serum, algorithm reported as risk of liver allograft rejection
0576U	Transplantation medicine (liver allograft rejection), donor-derived cfDNA by whole genome NGS, plasma and mRNA profiling by multiplex PCR of 56 genes, whole blood, combined algorithm reported as rejection risk score
0577U	Oncology (ovarian), serum, analysis of 39 glycoproteins by liquid chromatography with tandem mass spectrometry (lc-ms/ms) in multiple reaction monitoring mode, reported as likelihood of malignancy
0578U	Oncology (cutaneous melanoma), RNA gene expression profiling by realtime qPCR of 10 genes using FFPE tissue, algorithm reports binary result: low-risk or high-risk for sentinel lymph node metastasis and recurrence
0579U	Nephrology (diabetic chronic kidney disease), ELISA of apolipoprotein a4 , cd5 antigen-like combined with estimated glomerular filtration rate, age, plasma, algorithm reported as a risk score for kidney function decline
0580U	Borrelia burgdorferi, antibody detection of 24 recombinant protein groups, by immunoassay, igg
0581U	Transplantation medicine, antibody to non-human leukocyte antigens (nonhla), blood specimen, flow cytometry, single-antigen bead technology, 39 targets, individual positive antibodies reported
0582U	Rare diseases (constitutional disease/hereditary disorders), rapid whole genome dna sequencing for singlenucleotide variants, insertions/deletions, copy number variations, blood, saliva, tissue sample, variants reported
0583U	Rare diseases (constitutional/hereditary), rapid whole genome comparator DNA sequencing for SNVs, indels, CNVs, blood/saliva/tissue, variants reported with proband results (list separately with primary procedure code)
0584U	Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quakinginduced conformational conversion, qualitative
0585U	Targeted genomic sequence panel, solid organ neoplasm, cfDNA analysis from plasma of 521 genes for variants, amplifications, rearrangements, MSI; report shows identified mutations, including variants w/ clinical actionability
0586U	Oncology, mrna, gene expression profiling of 216 genes (204 targeted and 12 housekeeping genes), rna expression analysis, formalinixed paraffin-embedded (ffpe) tissue, quantitative, reported as log2 ratio per gene

Code	Description
0587U	Therapeutic drug monitoring, 60–150 drugs/metabolites, urine/saliva, quantitative LCMS/MS, specimen validity, algorithmic analyses for drug/metabolite presence or absence, risk score predicted for adverse drug effects
0588U	Infectious disease (bacterial or viral), 32 genes, immune response mRNA profiling by splitwell multiplex RT-LAMP, whole blood, reported as risk scores for infection and severe illness likelihood within the next 7 days
0589U	Perfluoroalkyl substances (pfas) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 24 pfas compounds by high-performance liquid chromatography with tandem mass spectrometry (lcms/ms), plasma or serum, quantitative
0590U	Infectious disease (bacterial and fungal), dna of 44 organisms (34 bacteria, 10 fungi), urine, next-generation sequencing, reported as positive or negative for each organism
0591U	Oncology (prostate cancer), biochemical analysis of 3 proteins (total PSA, free PSA, HE4), plasma/serum, prognostic algorithm w/ proteins & digital rectal exam, results reported as probability score for significant prostate CA
0592U	Oncology (hematolymphoid neoplasms), DNA targeted genomic sequencing of 417 genes for fusions, translocations, rearrangements using FFPE tumor tissue; results report clinically significant variant(s)
0593U	Infectious disease (genitourinary pathogens), dna, 46 targets (28 pathogens, 18 resistance genes), rt-pcr amplified probe technique, urine, each analyte reported as detected or not detected
0594U	Infectious disease (sepsis), semiquantitative measurement of pancreatic stone protein concentration, whole blood, reported as risk of sepsis
0595U	Infectious disease (tropical fever pathogens), vectorborne & zoonotic pathogens, including 2 viruses, 1 bacterium, and 1 parasite w/ species differentiation, real-time rtPCR, whole blood, ea pathogen reported as detected or not
0596U	Neurology (alzheimer disease), plasma, 3 distinct isoform-specific peptides (apoe2, apoe3, and apoe4) by liquid chromatography with tandem mass spectrometry (lcms/ms), reported as an apoe prototype
0597U	Oncology (breast), RNA expression profiling of 329 genes by targeted NGS and 20 proteins by multiplex immunofluorescence, FFPE tissue, algorithmic analyses to determine tumor-recurrence risk score
0598U	Gastroenterology (irritable bowel syndrome), igg antibodies to 18 food items by microarray-based immunoassay, whole blood or serum, report as elevated (positive) or normal (negative) antibody levels
0599U	Oncology (pancreatic cancer), multiplex immunoassay of icam1, timp1, ctsd, thbs1, and ca 19-9, serum, diagnostic algorithm reported as positive or negative

Table 6 – Deleted Codes

Code	Description
C9088	Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg
C9248	Injection, clevidipine butyrate, 1 mg
E0716	Supplies and accessories for intravaginal device intended to strengthen pelvic floor muscles during kegel exercises
J2150	Injection, mannitol, 25% in 50 ml
J2503	Injection, pegaptanib sodium, 0.3 mg
S0074	Injection, cefotetan disodium, 500 mg
0450U	Test for monoclonal paraproteins in blood, results reported as a baseline presence or absence of detectable clonotypic peptides in multiple myeloma
0451U	Testing paraproteins in blood, results compared to baseline results to determine monoclonal paraprotein abundance in multiple myeloma